Skip to main content

Market Overview

UPDATE: Oppenheimer Downgrades Chemtura to Perform on Limited Upside to Margin Improvement

Share:

Oppenheimer downgraded Chemtura (NYSE: CHMT) from Outperform to Perform and removed the price target of $24.00.

Oppenheimer noted, "CHMT continues to take significant strides structurally upgrading its business, the reason for our original Outperform, but things have changed to warrant a downgrade to Perform: 1) 2012 EPS growth of 29% was despite volume down 1%, and 4Q12 results showed that the company may be approaching the limits to further margin improvement without a healthier economy, thus we pare back estimates for 2013; 2) stock comp expense was previously understated, and 4Q saw a large $6M catch-up; 3) legacy overhead costs from the antioxidants sale will hamper margin; 4) mix deteriorated in petroleum additives; 5) 2013 capex needs are higher than expected; and 6) the stock was up 87% last year (vs. 13% for the S&P 500) and 3% YTD (vs. 4%)."

Chemtura closed at $21.96 on Monday.

Latest Ratings for CHMT

DateFirmActionFromTo
Nov 2016Gabelli & Co.DowngradesBuyHold
Oct 2016KeyBancDowngradesOverweightSector Weight
Oct 2016Seaport GlobalDowngradesBuyNeutral

View More Analyst Ratings for CHMT
View the Latest Analyst Ratings

 

Related Articles (CHMT)

View Comments and Join the Discussion!

Posted-In: OppenheimerAnalyst Color Downgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
FIBKStephens & Co.Downgrades
LEAFCanaccord GenuityDowngrades8.5
AGMSidoti & Co.Downgrades115.0
KEXGabelli & Co.Downgrades
OCGNCantor FitzgeraldDowngrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com